$3.65
-0.015-0.41%
Last update: Nov 6, 4:50 PM
Arbutus Biopharma Corp
ABUSNASDAQ
The average analyst price target for Arbutus Biopharma is $5.50, 50.7% above the current price. Of 4 analysts, 4 rate it Buy. Targets range from $5 to $7. The latest change came on Nov 20, 2024, when Chardan Capital raised its price target on Arbutus Biopharma from $4.50 to $5 and kept a Buy rating.
Price Target Range — 7 Quarters
Analyst Consensus — 4 Analysts
Rating Trend — Last 9 Months
